EMA committee recommends restricting Trobalt use

EMA's CHMP recommended restricting the use of seizure drug Trobalt retigabine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to last-line therapy in patients with partial epilepsy due to the risk of retinal pigmentation. CHMP, which said the benefit-risk balance for Trobalt "remains positive" in patients for whom other anti-epileptic medicines have proved inadequate or have not been tolerated, recommended patients currently taking the drug be reviewed at a routine appointment and new patients have a comprehensive eye exam at the start of treatment and at least every six months during treatment. ...